AstraZeneca is a global, science-led, and patient-focused biopharmaceutical company dedicated to developing, manufacturing, and marketing revolutionary treatments. With a strong emphasis on oncology, chronic diseases, rare diseases, biopharmaceuticals, and vaccines, AstraZeneca continues to redefine the healthcare landscape with cutting-edge innovations.
A Milestone in Global Health: The COVID-19 Vaccine
One of AstraZeneca’s most significant achievements was the development and launch of the AZD1222 vaccine, later renamed Vaxzevria. As the most widely used COVID-19 vaccine globally, it played a crucial role in pandemic response efforts. In Indonesia alone, 107.4 million doses were delivered, preventing an estimated 93,954 deaths.
Beyond vaccines, AstraZeneca’s commitment to public health continued with Evusheld, a long-acting antibody combination designed to protect those most vulnerable to COVID-19. These groundbreaking contributions reflect AstraZeneca’s unwavering commitment to scientific innovation and patient care.
What Puts AstraZeneca at the Top
AstraZeneca Indonesia has been recognized as the number one multinational pharmaceutical company in Indonesia according to IQVIA Market Data 2022. Its continued success stems from a combination of scientific leadership, sustainability efforts, strong commercialization capabilities, and a commitment to innovation.
Scientific Leadership and Innovation
AstraZeneca is at the forefront of scientific breakthroughs, developing next-generation therapeutics such as advanced biologics, nucleotide-based drugs, and cell therapies. The company integrates science, data, and technology to create transformative medicines, addressing the world’s growing disease burden.
Sustainability and Social Responsibility
AstraZeneca operates with a long-term vision, balancing business growth with societal and environmental needs. By investing in sustainability initiatives, AstraZeneca generates both financial and non-financial value that benefits patients, healthcare systems, and communities worldwide.
The 5R Framework: A Commitment to Excellence in R&D
AstraZeneca’s 5R Framework—Right Target, Right Tissue, Right Safety, Right Patient, Right Commercial—has revolutionized its approach to drug discovery and development. Over the last decade, the company has improved the success rate of its pipeline molecules from 4 percent to 23 percent, far surpassing the 14 percent industry average between 2018 and 2020.
Strong Manufacturing and Commercialization Capabilities
With a robust research, development, and manufacturing network, AstraZeneca ensures that medicines reach patients efficiently. In 2022, the company achieved a 19 percent increase in total revenue, reaching 44.4 billion dollars, driven by existing products, new medicine launches, and strategic collaborations. This growth reinforces AstraZeneca’s trajectory toward industry-leading revenue expansion through 2025 and beyond.
A Proven Track Record in Medicine Development
AstraZeneca has launched 20 new medicines over the past decade, with three debuting in 2022 alone. These launches highlight the company’s ability to deliver innovative treatments that address critical medical needs.
Blockbuster Medicines and Market Approvals
With 14 blockbuster medicines, each generating over 1 billion dollars in annual revenue, AstraZeneca stands as a powerhouse in the biopharmaceutical industry. In 2022, the company secured 34 major market approvals, further cementing its leadership position in Asia and beyond.
Fighting the COVID-19 Pandemic
Beyond vaccine development, AstraZeneca demonstrated a deep commitment to global health by providing millions of COVID-19 vaccine doses at no profit during the pandemic’s worst phases. In Indonesia alone, this initiative not only saved millions of lives but also prevented an estimated 8.1 billion dollars in pandemic-related healthcare costs.
Empowering a Global Workforce
AstraZeneca’s strength lies in its people. In 2022, the company nurtured 83,500 employees worldwide, fostering an inclusive, high-performing culture. This included 555 performance development workshops for 16,500 participants and a dynamic recognition system, with 269,000 rewards given to 68 percent of employees—20 percent of whom were recognized for cross-functional collaboration.
Diversity and inclusion remain core values, with 52.9 percent of the global workforce comprising women. The leadership team reflects this commitment, with five women making up 38 percent of the Board. Additionally, 83 percent of AstraZeneca employees reported feeling comfortable expressing their opinions—a testament to the company’s dedication to an open and empowering work environment.
AstraZeneca: Shaping the Future of Healthcare
With a relentless pursuit of scientific excellence, a strong commitment to sustainability, and an unwavering focus on patient-centric innovation, AstraZeneca continues to lead the way in the biopharmaceutical industry. Through groundbreaking treatments, strategic global initiatives, and a thriving workforce, AstraZeneca remains dedicated to transforming healthcare and improving lives worldwide.
